Moderna (MRNA) Cash from Operations (2018 - 2026)
Moderna (MRNA) posted quarterly Cash from Operations of 526000000.0 for Q2 2026, up 42.76% year-over-year from 368440548.78 in Q2 2025, and up 16.51% on a QoQ basis from 630000000.0 in Q1 2026.
Moderna (MRNA) Cash from Operations (2018 - 2026) Analysis & Trends
Moderna has reported Cash from Operations for 9 years, with the latest figure at 526000000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 526000000.0, up 42.76% year-over-year; the trailing twelve-month figure through Jun 2026 was 1073000000.0 (up 60.22% YoY), and the FY2025 annual result was 1873000000.0, up 37.65% from the prior year.
- Cash from Operations rose to 526000000.0 in Q2 2026, from 630000000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2763000000.0 in Q1 2022 and troughed at 1600000000.0 in Q3 2023.
- A 5-year average of 231666666.67 and a median of 738500000.0 in 2025 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2023, when Cash from Operations plunged 734.92%; it then soared 45.91% in 2025.
- A 5-year view of Cash from Operations shows it stood at 1662000000.0 in 2022, then tumbled by 62.58% to 622000000.0 in 2023, then jumped by 32.64% to 825000000.0 in 2024, then gained by 12.73% to 930000000.0 in 2025, then slumped by 156.56% to 526000000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 526000000.0 in Q2 2026, 630000000.0 in Q1 2026, and 930000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | -526.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -526.00 Mn |
| Jun 30, 2026 | -526.00 Mn |
| Mar 31, 2026 | -630.00 Mn |
| Mar 31, 2026 | -630.00 Mn |
| Dec 31, 2025 | 930.00 Mn |
| Dec 31, 2025 | 930.00 Mn |
| Sep 30, 2025 | -847.00 Mn |
| Sep 30, 2025 | -847.00 Mn |
| Jun 30, 2025 | -919.00 Mn |
| Jun 30, 2025 | -919.00 Mn |
| Mar 31, 2025 | -1.04 Bn |
| Mar 31, 2025 | -1.04 Bn |
| Dec 31, 2024 | 825.00 Mn |
| Dec 31, 2024 | 825.00 Mn |
| Sep 30, 2024 | -1.57 Bn |
| Sep 30, 2024 | -1.57 Bn |
| Jun 30, 2024 | -1.27 Bn |
| Jun 30, 2024 | -1.27 Bn |
| Mar 31, 2024 | -989.00 Mn |
| Mar 31, 2024 | -989.00 Mn |